|Institute for Research & Innovation|
- Institute for Research & Innovation
- About Us
- Participate in a Study
- Become an Investigator
- Information for Sponsors
Multiple Sclerosis - Neuropathic PainTitle: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis
Purpose: This study is seeking patients who have clinically diagnosed MS-related central neuropathic pain, but are otherwise in generally good health.
Who Can Participate? Patients who have been diagnosed with MS-related central neuropathic pain for at least 90 days prior to study participation. Patient may be on any or no MS modifying therapy.
Diagnosis or Condition: Patients with a clinical diagnosis of Multiple Sclerosis
Medication: Investigational Product is delivered via oral capsule twice daily.
Age: Between 18 and 85 years of age
Sex: Males and Females
Visits: Seven visits over a period of 13 weeks
Stipend: You will be compensated for your time and travel
Principal Investigator(s): John Huddlestone, MD, FAAN
Study Coordinator: Andrea Thompson, 253-403-7440